The largest database of trusted experimental protocols

9 protocols using stat5 in 1

1

Activation and Inhibition of Naive CD8+ T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mouse naive CD8+ T cells were negatively selected by EasySep Mouse Naive CD8+ T Cell Isolation Kit (STEMCELL). Isolated naive CD8+ T cells were cultured in RPMI-1640 medium with 10% FBS, 1% penicillin, and 100 μg/mL streptomycin in flat-bottom plates precoated with anti-CD3 (2 μg/mL; clone 145-2C11; eBioscience) and anti-CD28 (2 μg/mL; clone 37.51; eBioscience) for 2 days, unless otherwise stated. For small molecular inhibitor treatment, Stattic (Selleck, S7024), SH-4-54 (Selleck, S7337), STAT5-IN-1 (Selleck, S6784), or 17-AAG (Selleck, S1141) was added to culture medium and cells were cultured for indicated times.
+ Open protocol
+ Expand
2

STAT5 Inhibition in Carotid Plaque Cultures

Check if the same lab product or an alternative is used in the 5 most similar protocols
Atherosclerotic plaque samples obtained during carotid endarterectomy from 4-10 symptomatic patients (Supplemental Table 2) were collected in the Maastricht Pathology Tissue Collection (MPTC) in line with the Dutch Code for Proper Secondary Use of Human Tissue (http://www.fmwv.nl) and the local Medical Ethical Committee (protocol number 16-4-181). This study conforms to the Declaration of Helsinki. The endarterectomy specimens were cut into 2 mm thick sections. Subsequently, the sections were cultured in RPMI1640 (Thermofisher) supplemented with 0.1% FCS and 1% PenStrep (Gibco) and cultured in a controlled environment (37°C, 5% CO2) for 24 hours in presence of the general STAT5 inhibitor STAT5-in-1 (300 µM, Selleck Chemicals) or the STAT5A-specific inhibitor POM-CHF-Stafia-1 (50 µM, Supplemental Figure 1) (25 (link)). Control sections and inhibitor treated sections were alternating. Control sections were treated with DMSO concentration equal to the inhibitors. A multiplex ELISA was performed on the plaque-conditioned medium as described above.
+ Open protocol
+ Expand
3

Organoid Viability: Vitamin, Inhibitor Effects

Check if the same lab product or an alternative is used in the 5 most similar protocols
To evaluate the effects of vitamin A, vitamin D, signal transducers and activators of transcription 5 (STAT5)-inhibitor STAT5-IN-1, or p38 mitogen-activated protein kinase (p38 MAPK)-inhibitor SB203 580 (5 µM, solved in DMSO; Sigma-Aldrich, Darmstadt, Germany) on organoid cell viability, an MTT reduction assay was performed. For this purpose, organoids were incubated with calcitriol (50 nM, 100 nM, 200 nM, solved in DMSO; Sigma-Aldrich, Darmstadt, Germany), or with retinoic acid (10 µM, 100 µM, 200 µM, solved in DMSO; Sigma-Aldrich, Darmstadt, Germany), or with STAT5-IN-1 (5 µM, 0.5 mM, 1 mM, solved in DMSO; Selleckchem, Planegg, Germany), or with SB203 580 (5 µM, solved in DMSO; Sigma-Aldrich, Darmstadt, Germany), or with a corresponding amount of DMSO as control for 30 h. Then, MTT solution (500 µg/mL; solved in PBSO; Merck, Darmstadt, Germany) was added to organoids to a final concentration of 500 µg/mL. After incubation for 1 h at 37 °C, 5% CO2, CCM was discarded and cells were incubated with 20 µL of SDS (for 1 h at 37 °C, 5% CO2) to dissolve Matrigel. Finally, 100 µL of DMSO was added (for 1 h at 37 °C, 5% CO2) to dissolve reduced MTT, and the optical density was measured at 562 nm on a microplate absorbance reader (BioTek Instruments, Winooski, VT, USA).
+ Open protocol
+ Expand
4

Immunoblotting Analysis of Phospho-Proteins

Check if the same lab product or an alternative is used in the 5 most similar protocols
Antibodies against phospho-AKT(Ser473), ERK, phospho-ERK(Thr202/Tyr204), STAT5, and phospho-STAT5 were obtained from Cell Signaling Technology (Danvers, MA); anti-KIT from R&D Systems (Minneapolis, MN) and Santa Cruz Biotechnology (Santa Cruz, CA); anti-phospho-KIT(Tyr823) from Invitrogen (Carlsbad, CA); anti-AKT from BD Biosciences (San Diego, CA); and anti-β actin from Sigma Aldrich (St. Louis, MO); and anti-rabbit IgG 800CW and anti-mouse IgG 680 RD from Licor Biosciences (Lincoln, NE). Human TruStain FcX and APC-conjugated anti-human c-KIT (clone 104D2), unlabeled anti-human KIT antibody (clone 104D2) and Zombie Aqua fixable viability dye were obtained from Biolegend (San Diego, CA); KIT antibody for IHC from Dako-Agilent (Santa Clara, CA); human SCF from R & D Systems; avapritinib, imatinib, dasatinib, midostaurin, fedratinib, STAT5-IN-1, SH4-54, venetoclax, ripretinib (DCC-2618), ruxolitinib, tofacitinib, and C188-9 from SelleckChem (Houston, TX); LY294002 and U0126 from Tocris (Minneapolis, MN); Pierce BCA assay and CyQuant cell proliferation assay from Thermo Fisher Scientific (Waltham, MA); and ViaStain propidium iodide (PI) staining solution from Nexelom Biosciences (Lawrence, MA).
+ Open protocol
+ Expand
5

STAT5 Inhibition in Carotid Plaque Cultures

Check if the same lab product or an alternative is used in the 5 most similar protocols
Atherosclerotic plaque samples obtained during carotid endarterectomy from 4-10 symptomatic patients (Supplemental Table 2) were collected in the Maastricht Pathology Tissue Collection (MPTC) in line with the Dutch Code for Proper Secondary Use of Human Tissue (http://www.fmwv.nl) and the local Medical Ethical Committee (protocol number 16-4-181). This study conforms to the Declaration of Helsinki. The endarterectomy specimens were cut into 2 mm thick sections. Subsequently, the sections were cultured in RPMI1640 (Thermofisher) supplemented with 0.1% FCS and 1% PenStrep (Gibco) and cultured in a controlled environment (37°C, 5% CO2) for 24 hours in presence of the general STAT5 inhibitor STAT5-in-1 (300 µM, Selleck Chemicals) or the STAT5A-specific inhibitor POM-CHF-Stafia-1 (50 µM, Supplemental Figure 1) (25 (link)). Control sections and inhibitor treated sections were alternating. Control sections were treated with DMSO concentration equal to the inhibitors. A multiplex ELISA was performed on the plaque-conditioned medium as described above.
+ Open protocol
+ Expand
6

Regulatory T Cell Modulation by YQJD and STAT5 Inhibitor

Check if the same lab product or an alternative is used in the 5 most similar protocols
CD4+CD25+ Treg cells were isolated using blank mouse spleen cells with a CD4+CD25+ Treg cell isolation kit (mouse, MACS, 130-091-041). The cells were then cultured in RPMI 1640 complete medium at 37°C in a humidified atmosphere containing 5% CO2. This experiment included three groups: a YQJD group (reaching a drug serum concentration of 10%), a YQJD + STAT5 inhibitor (STAT5-IN-1, Selleckchem, SH-4-54) treatment group, and a mock-treated blank control group. Treg cells (2  × 105 cells/mL) were plated on RPMI 1640 supplemented with 35 μL of anti-CD3/CD28 antibodies and 5 ng/ml IL-2 for 72 h. The YQJD + STAT5 inhibitor group was treated with 50 μM STAT5 inhibitor. Finally, cultured cells were collected for western blotting and flow cytometry.
+ Open protocol
+ Expand
7

AhR Regulates CD8+ T Cell Response

Check if the same lab product or an alternative is used in the 5 most similar protocols
For the infection model, 1 × 104 CFUs of Lm-OVA were administrated into 6- to 8-wk-old female AhR−/− and WT C57BL/6 mice intravenously, bacterial loads in the spleen and liver were analyzed 48 h after infection. OVA-specific CD8+ T cells in the spleen, lymph nodes, blood, and lungs were analyzed by flow cytometry on day 7. On day 30, the mice were re-challenged with 1 × 106 CFU Lm-OVA, and the bacterial burdens in the spleen and liver were analyzed. For the OT-I transfer experiment, 1 × 105shAhR-CD8+ T cells or shNC-CD8+ OT-I T cells were transferred into 6-8-week-old female CD45.2 recipients. One day after OT-I cell transfer, 5 × 105 CFUs of Lm-OVA were administrated intravenously. In some studies, 1 × 105 CD8+ Tn cells isolated from CD45.1+ OT-I mice were transferred into 6- to 8-wk-old female CD45.2 recipients. Ten mg/kg CH223191(Selleck, S7711), 5 mg/kg STAT5 inhibitor (STAT5-IN-1; Selleck), or 5 mg/kg Tph1 inhibitor (CP-10188, Selleck) were administrated intraperitoneally everyday according to the experimental needs.
Analysis or sorting of MPECs (CD127high KLRG1low) and SLECs (CD127low KLRG1high) was conducted from the spleen of mice infected with Lm-OVA on day 10, which had been previously transferred with CD8+ OT-I T cells.
+ Open protocol
+ Expand
8

Organoid Treatment with Calcitriol and Retinoic Acid

Check if the same lab product or an alternative is used in the 5 most similar protocols
Organoids were treated with calcitriol (50 nM; solved in in DMSO; Sigma-Aldrich, Darmstadt, Germany), or retinoic acid (10 µM, solved in DMSO; Sigma-Aldrich, Darmstadt, Germany), or corresponding amount of DMSO as control for 30 h. Furthermore, cells were incubated with retinoic acid or calcitriol and STAT5-IN-1 (5 µM, solved in DMSO; Selleckchem, Planegg, Germany), or SB203 580 (5 µM, solved in DMSO; Sigma-Aldrich, Darmstadt, Germany) for 30 h. A corresponding amount of DMSO was used as a control.
+ Open protocol
+ Expand
9

Organoid Immune Response Modulation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Organoids were treated with HD51–9 (1.17 µM, solved in BSA/PBSO), or hBD2 (0.027 µM, solved in BSA/PBSO), or corresponding amount of BSA/PBSO as control for 30 h. Furthermore, cells were incubated with HD51–9 or hBD2 and STAT3-inhibitor HJC015233 (5 µg, solved in DMSO; Selleckchem, Houston, TX, USA), or STAT5-inhibitor STAT5-IN-1 (5 µM, solved in DMSO; Selleckchem, Planegg, Germany), or p38 inhibitor SB203 580 (5.303 mM, solved in DMSO; Sigma-Aldrich, Darmstadt, Germany), or Myd88 inhibitor TJ-M2010-5 (100 µM, solved in DMSO; MedChemExpress, Sollentuna, Sweden) for 30 h. A corresponding amount of DMSO was used as a control.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!